Nidha Shapoo

Dr. Nidha Shapoo

Internal Medicine Metropolitan Hospital, New York Medical College, Valhalla, USA
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2025 in Health Care Science
Verified
Journal Article
Open access
NSNidha Shapoo
Nidha Shapoo
NSNaveed Shapoo
Naveed Shapoo
ARAbdul Rehman
Abdul Rehman
NBNoella Boma
Noella Boma
Digital health is transforming healthcare by integrating advanced technologies to make healthcare more accessible, efficient, and personalized. From electronic health records, telemedicine, wearable devices, and artificial intelligence to the recent smart hospitals, digital health is improving patient care and outcomes while reducing healthcare costs. However, the integration of digital health faces several challenges, including data privacy, cybersecurity risks, and inequitable access to technology. This article provides an overview of the current state of digital health, key challenges in implementation, and potential solutions to maximize the benefits of digital health and ensure efficient, equitable, and patient‐centered healthcare in the future.

23 September 2025 in Clinics and Practice
Verified
Journal Article
Open access
PDF file
NSNidha Shapoo
Nidha Shapoo
ARAbdul Rehman
Abdul Rehman
CRCARLOS ALBERTO IZAGUIRRE ROJAS
CARLOS ALBERTO IZAGUIRRE ROJAS
VGVladimir Gotlieb
Vladimir Gotlieb
NBNoella Boma
Noella Boma
Cancer pain remains a significant challenge in oncology, profoundly affecting patients’ quality of life, function, and prognosis. Historically under-recognized and managed with a uniform, opioid-centric approach, cancer pain was often inadequately treated. Advances in pain assessment, multimodal analgesia, and supportive care have improved outcomes, yet traditional algorithms frequently fail to address the complex, heterogeneous nature of cancer pain. Contemporary management is shifting toward precision and personalized medicine, integrating genetic, molecular, and biomarker data with individual patient characteristics to inform treatment decisions. To address this complexity, we propose a five-domain framework encompassing biological, pharmacologic, psychological, sociocultural, and functional domains. This multidimensional approach enables clinicians to tailor pain management strategies to each patient’s unique profile, aiming for equitable and individualized care. However, challenges remain, including tumor and patient heterogeneity, limited biomarker validation, data integration, disparities in access, and the need for multidisciplinary coordination. This review traces the evolution of cancer pain management, highlights the promise of precision and personalized strategies, and presents a comprehensive framework for optimizing pain control in oncology.

13 June 2013 in Case Reports in Oncological Medicine
Verified
Journal Article
Open access
PDF file
NSNidha Shapoo
Nidha Shapoo
ASAtul Sharma
Atul Sharma
Malignancy is known to be one of the predisposing factors of cerebral venous thrombosis (CVT) due to its hypercoagulable state. CVT is a rare disorder which can lead to frequent misdiagnoses of brain metastases in such cases. We report here the case of a 35-year-old female with metastatic colon adenocarcinoma presenting with sudden neurological symptoms. Brain MRI and magnetic resonance venography confirmed the presence of CVT. She was treated with low molecular weight heparin followed by warfarin. She recovered and is doing well on warfarin after 5 months of diagnosis of CVT. CVT should be strongly suspected as a cause of neurological dysfunction in any case of disseminated malignancy including colon adenocarcinoma. Rapid diagnosis and initiation of therapy should be considered because of its favourable outcome.

18 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
NSNidha Shapoo
Nidha Shapoo
ARAbdul Rehman
Abdul Rehman
VGVladimir Gotlieb
Vladimir Gotlieb
NBNoella Boma
Noella Boma
Cancer pain remains a significant challenge in oncology, profoundly affecting patients’ quality of life, function, and prognosis. Historically under-recognized and managed with a uniform, opioid-centric approach, cancer pain was often inadequately treated. Advances in pain assessment, multimodal analgesia, and supportive care have improved outcomes, yet traditional algorithms frequently fail to address the complex, heterogeneous nature of cancer pain. Contemporary management is shifting toward precision and personalized medicine, integrating genetic, molecular, and biomarker data with individual patient characteristics to inform treatment decisions. To address this complexity, we propose a five-domain framework encompassing biological, pharmacologic, psychological, sociocultural, and functional domains. This multidimensional approach enables clinicians to tailor pain management strategies to each patient’s unique profile, aiming for equitable and individualized care. However, challenges remain, including tumor and patient heterogeneity, limited biomarker validation, data integration, disparities in access, and the need for multidisciplinary coordination. This review traces the evolution of cancer pain management, highlights the promise of precision and personalized strategies, and presents a comprehensive framework for optimizing pain control in oncology.

5 February 2025 in Hematology Reports
Verified
Journal Article
Open access
PDF file
NSNidha Shapoo
Nidha Shapoo
NBNoella Boma
Noella Boma
SCShobhana Chaudhari
Shobhana Chaudhari
VGVladimir Gotlieb
Vladimir Gotlieb
Coagulation disorders are increasingly recognized as significant complications in patients with solid tumors, affecting morbidity and mortality outcomes. Solid tumors can provoke a hypercoagulable state through the release of pro-coagulant factors, endothelial activation, and inflammation, leading to a heightened risk of coagulation disorders. These coagulation disorders may manifest as venous thromboembolism, arterial thromboembolism, thrombotic microangiopathy, or disseminated intravascular coagulation. These disorders can complicate surgical interventions and impact treatments, including chemotherapy and immunotherapy efficacy, leading to poor outcomes. Understanding the implications of coagulation disorders in solid tumors is essential for optimizing patient management, including identifying high-risk patients, implementing prophylactic measures, elucidating biomarkers for clinical outcomes, and exploring novel therapeutic agents. This review aims to provide insights into the current knowledge surrounding coagulation disorders in solid tumors and their clinical implications.

1 May 2025 in Journal of Investigative Medicine High Impact Case Reports
Verified
Journal Article
Open access
NSNidha Shapoo
Nidha Shapoo
RARehman Abdul
Rehman Abdul
MJMattana Joseph
Mattana Joseph
JWJenchin Wang
Jenchin Wang
GVGotlieb Vladimir
Gotlieb Vladimir
Cemiplimab is a programmed death receptor-1 inhibitor that has been approved for the treatment of advanced cutaneous squamous cell carcinoma (CSCC). The immune-related adverse events most commonly reported with cemiplimab are thyroiditis, pneumonitis, and hepatitis. Ocular adverse events have been rarely reported. We present a rare case of Vogt-Koyanagi-Harada (VKH)-like syndrome in a patient with CSCC being treated with cemiplimab. A 53-year-old woman presented with bilateral progressive visual disturbances, eye pain, and headache for 4 weeks after 4 cycles of neo-adjuvant cemiplimab therapy for stage IV CSCC of the lower back. The detailed ophthalmologic evaluation established the diagnosis of VKH-like syndrome with panuveitis, subretinal fibrosis, and exudative retinal detachment. The patient received high-dose intravenous and topical steroids followed by a gradual taper of oral steroids over 6 months. Cemiplimab was discontinued. There was significant improvement in her symptoms with the resolution of subretinal fluid, choroidal elevations, and retinal detachment. VKH-like syndrome is an immune-mediated disorder that affects pigmented structures and is a significant cause of noninfectious uveitis. Drug-related uveitis has been seen more commonly with immune checkpoint inhibitors than with other drug classes and can occur anytime during the treatment. The mainstay of treatment of VKH-like syndrome is high-dose intravenous corticosteroids. In resistant cases, immunosuppressive therapies and biological agents are beneficial. This case highlights the importance of prompt recognition of VKH-like syndrome associated with cemiplimab, enabling timely intervention to prevent permanent vision loss.